Evry, France, and Bergisch Gladbach, Germany – Genethon, a leader in the field of gene therapy treatments for rare diseases, and Miltenyi Biotec, a global front-runner in cell processing and related technologies in cell therapy, have announced the execution of an exclusive license to the patents and trademarks for the development and commercialization of Vectofusin-1® by Miltenyi Biotec. As part of this agreement, Miltenyi Biotec has also acquired the right to grant sublicenses to its customers.

Vectofusin-1 is a novel viral transduction enhancer that promotes the adhesion and fusion between viral and cellular membranes. The use of Vectofusin-1® diminishes technical limitations the gene therapy field is confronted with, by enhancing target cell transduction levels and reducing the amount of viral particles required. This opens up possibilities to develop reliable gene therapy protocols with optimized efficiency, higher safety standards and reduced cost.

Research-grade Vectofusin-1® for basic